Short answer
Nuvation Bio Inc. (NUVB) filed its Q3 2025 10-Q quarterly report on Nov 3, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $13M (up 1704.7% year over year) with net income of −$56M.
Q3 2025 key financials · XBRL
- Revenue
- $13M
- +1704.7% YoY · +171.5% QoQ
- Net income
- −$56M
- −35.4% YoY · +5.4% QoQ
- Operating margin
- -430.1%
- Gross margin
- 74.5%
- EPS (diluted)
- −$0.16
- −220.0% YoY · +5.9% QoQ
Source: XBRL data from the Nuvation Bio Inc. (NUVB) Q3 2025 10-Q on SEC EDGAR. USD.
Nuvation Bio Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: FDA post-marketing regulatory requirements for IBTROZI since June 2025 approval, with potential penalties or product withdrawal for non-compliance
- Updated commercial risk: Initiation of U.S. commercial launch of IBTROZI, highlighting risks in marketing, sales experience, and limited patient population estimates
- Regulatory risk: Uncertainty in coverage and reimbursement by U.S. Medicare, Medicaid, and China's National Reimbursement Drug List (NRDL) affecting pricing and patient access
- Operational risk: Dependence on third-party distributors and specialty pharmacies for IBTROZI distribution with risks of failure impacting revenues and reputation
- Financial risk: Need for substantial capital to fund commercialization and operations, with indebtedness potentially constraining funding flexibility
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Nuvation Bio Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.